Clinical trial
Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With…
NCT00002395 · SmithKline Beecham, Industry · Completed
Key facts
| NCT number | NCT00002395 |
|---|---|
| Title | Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML) |
| Official title | An Open, Comparative Phase II Study of Immediate Versus Delayed Treatment With Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy |
| Lead sponsor | SmithKline Beecham, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Leukoencephalopathy, Progressive Multifocal |
| Intervention type | Drug |
| Interventions | Topotecan |
| Enrollment | 54 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: